EUVIMEDEUVIMED entdecken
Crossref

Discovery of Palindrome Dual PPARγ‐GPR40 Agonists for Treating Type 2 Diabetes

Ana Rodríguez-Luévano, Julio C Almanza-Pérez, Rolffy Ortiz-Andrade, Samuel Lara-González, Rosa Santillán, Gabriel Navarrete-Vázquez, Abraham Giacoman-Martínez, Roberto C Lazzarini-Lechuga, Elihú Bautista, Sergio Hidalgo-Figueroa iD

ChemMedChem · 2024

DOI: 10.1002/cmdc.202400492 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemMedChem, 2024. Verfasst von Ana Rodríguez-Luévano und 9 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Posgrado en Biología Molecular, División de Biología Molecular, Institution Instituto Potosino de Investigación Científica y Tecnológ…. Hauptthemen laut MEDLINE: PPAR gamma, Diabetes Mellitus, Type 2, Receptors, G-Protein-Coupled, Hypoglycemic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 67 Literaturangaben. Gefördert von: Ciencias y Tecnologías, FORDECYT, FORDECYT-PRONACES.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This work describes a first attempt of palindromic design for dual compounds that act simultaneously on peroxisome proliferator‐activated receptor gamma (PPARγ) and G‐protein‐coupled receptor 40 (GPR40) for the treatment of type 2 diabetes. The compounds were synthesized by multi‐step chemical reactions and the relative mRNA expression levels of PPARγ, GPR40, and GLUT‐4 were measured in cultured C2 C12 muscle cells and RIN‐m5 f β‐pancreatic cells. In addition, insulin secretion and GLUT‐4 translocation were measured. Compound 2 displayed a moderate increase in the mRNA expression of PPARγ and GPR40. However, the translocation of the GLUT‐4 transporter was 400 % with a similar effect to pioglitazone. The in vivo effect of compound 2 was determined at 25 mg/kg single dose using a normoglycemic and non‐insulin dependent diabetes mellitus (NIDDM) rat models. Compound 2 showed basal plasma glucose in diabetic rats with feed intake, which is associated with the moderate release of insulin measured in cells. Surprisingly, the glucose does not decrease in normoglycemic rats. Compound 2 maintained significant interactions with the GPR40 and PPARγ receptors during molecular dynamics. Altogether, the results demonstrate that compound 2 , with a palindromic design, simultaneously activates PPARγ and GPR40 receptors without inducing hypoglycemia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PPAR gammaDiabetes Mellitus, Type 2Receptors, G-Protein-CoupledHypoglycemic AgentsAnimalsRatsMaleDiabetes Mellitus, ExperimentalGlucose Transporter Type 4Structure-Activity RelationshipMolecular StructureDrug DiscoveryDose-Response Relationship, DrugHumansMolecular Docking SimulationBlood Glucose

Stichwörter der Autor:innen

DiabetesGPR40Molecular dynamicsPPARγPalindromic design

Substanzen

PPAR gammaReceptors, G-Protein-CoupledHypoglycemic AgentsG-protein-coupled receptor 40, ratGlucose Transporter Type 4Blood Glucose

Autor:innen und Institutionen

  • Departamento de Posgrado en Biología Molecular, División de Biología Molecular, Institution Instituto Potosino de Investigación Científica y Tecnológica (IPICYT), S.L.P, San Luis Potosí, 78216, México.
  • Laboratorio de Farmacología, Depto. Ciencias de La Salud, D.C.B.S, Universidad Autónoma Metropolitana- Iztapalapa, CDMX, CP 09340, México.
  • Área de Farmacología Experimental, Laboratorio de Farmacología, Facultad de Química, Universidad Autónoma de Yucatán., Calle 43 No. 613 X Calle 90, Colonia Inalámbrica, Mérida, Yucatán, 97069, México.
  • División de Biología Molecular, Instituto Potosino de Investigación Científica y Tecnológica A. C., San Luis Potosí, 78216, México.
  • Departamento de Química, Centro de Investigación y Estudios Avanzados del Instituto Politécnico Nacional, Avenida IPN 2508, CDMX, 07330, México.
  • Facultad de Farmacia, Universidad Autónoma Del Estado de Morelos, Cuernavaca, Morelos, 62209, México.

ORCID-Profile: Sergio Hidalgo-Figueroa

Förderung

  • Ciencias y Tecnologías
  • FORDECYT
  • FORDECYT-PRONACES
  • Doctoral Scholarship

Zitieren

APA

Rodríguez-Luévano, A., Almanza-Pérez, J. C., Ortiz-Andrade, R., Lara-González, S., Santillán, R., Navarrete-Vázquez, G., Giacoman-Martínez, A., Lazzarini-Lechuga, R. C., Bautista, E., & Hidalgo-Figueroa, S. (2024). Discovery of Palindrome Dual PPARγ‐GPR40 Agonists for Treating Type 2 Diabetes. ChemMedChem. https://doi.org/10.1002/cmdc.202400492

Vancouver

Rodríguez-Luévano A, Almanza-Pérez JC, Ortiz-Andrade R, Lara-González S, Santillán R, Navarrete-Vázquez G, et al. Discovery of Palindrome Dual PPARγ‐GPR40 Agonists for Treating Type 2 Diabetes. ChemMedChem. 2024. doi:10.1002/cmdc.202400492

BibTeX
@article{RodrguezLuvano2024,
  author = {Rodríguez-Luévano, Ana and Almanza-Pérez, Julio C and Ortiz-Andrade, Rolffy and Lara-González, Samuel and Santillán, Rosa and Navarrete-Vázquez, Gabriel and Giacoman-Martínez, Abraham and Lazzarini-Lechuga, Roberto C and Bautista, Elihú and Hidalgo-Figueroa, Sergio},
  title = {Discovery of Palindrome Dual PPARγ‐GPR40 Agonists for Treating Type 2 Diabetes},
  journal = {ChemMedChem},
  year = {2024},
  doi = {10.1002/cmdc.202400492}
}
Kostenlos starten →